Haiti
Tuberculosis profile
| High HIV burden |
Population  2013 10 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.7 (1.5–4.2) 26 (14–41)
Mortality (HIV+TB only) 0.88 (0.69–1.1) 8.5 (6.7–10)
Prevalence  (includes HIV+TB) 26 (13–43) 254 (129–421)
Incidence  (includes HIV+TB) 21 (18–24) 206 (179–231)
Incidence (HIV+TB only) 4.4 (3.8–5) 43 (37–48)
Case detection, all forms (%) 80 (72–92)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 2.2 (1.3–3.1) 14 (4.7–22)
MDR-TB cases among notified pulmonary
TB cases
320 (190–450) 65 (23–110)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 9 830   483
Pulmonary, clinically diagnosed 4 732    
Extrapulmonary 1 995    
       
Total new and relapse 17 040    
Previously treated, excluding relapses 0    
Total cases notified 17 040    
Among 17 040 new and relapse cases:
1 905 (11%) cases aged under 15 years; male:female ratio: 1.1
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 0 (0%) 101 (21%) 101
Laboratory-confirmed RR-/MDR-TB cases     101
Patients started on MDR-TB treatment     81
TB/HIV 2013 Number (%)
TB patients with known HIV status 14 668 (86)
HIV-positive TB patients 2 857 (19)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 2 119 (74)
HIV-positive TB patients on antiretroviral therapy (ART) 1 661 (58)
HIV-positive people screened for TB 2 309  
HIV-positive people provided with IPT 19 199  
Treatment success rate (%)
New and relapse cases registered in 2012 81
Previously treated cases, excluding relapse, registered in 2012 67
HIV-positive TB cases, all types, registered in 2012 70
RR-/MDR-TB cases started on second-line treatment in 2011 69
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 2.2
Culture (per 5 million population) 1.0
Drug susceptibility testing (per 5 million population) 1.0
Sites performing Xpert MTB/RIF 6
Is second-line drug susceptibility testing available? Yes, in and outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) 12
% Funded domestically 5%
% Funded internationally 34%
% Unfunded 61%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-04-21 Data: www.who.int/tb/data